Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results

• DOI: 10.1186/s13014-020-01608-1
• Publication Date: 2020-07-14T13:38:34Z
• Authors: Kristiina Vuolukka; Päivi Auvinen; Erno Tiainen; Jan-Erik Palmgren; Janne Heikkilä; Jan Seppälä; Sirpa Aaltomaa; Vesa Kataja
• Keywords: Cyberknife; Biochemical recurrence

Abstract Background The use of stereotactic body radiotherapy (SBRT) as the primary treatment modality in clinically localized prostate cancer (PCa) is emerging. aim study was to analyze long-term results PCa patients treated with SBRT. Methods This non-selected, real-life patient cohort included 213 a robotic SBRT device during 2012–2015. Results median follow-up 64 months (range, 10–85 months), and all risk-groups were represented 47 (22.1%), 56 (26.3%) 110 (51.6%) classified into D’Amico risk stratification low, intermediate high-risk groups, respectively. Androgen deprivation therapy (ADT) administered 64.3% patients. At cut-off, biochemical relapse-free survival (bRFS) 100, 87.5 80.0% for at ( p = 0.004), 92.5, 84.2 66.7% Gleason score ≤ 6, 7 ≥ 8, respectively 0.001). actuarial 5-year overall (OS) rates 97.9, 96.4 88.6% respectively, disease-specific (DSS) rate whole high (99.1%), only two died due PCa. Conclusion Our present delivered CyberKnife produced excellent bRFS, OS DSS outcomes among We conclude that provides an efficient convenient option PCa, irrespective risk-group.